Fatigue is recognized as the most serious complication of chemotherapy for the majority of patients. This study aims to determine preferences and utility values for health state descriptions of anemia associated with cancer treatment.
FACT-An clinical trial data were summarized to define health states associated with hemoglobin levels of 7.0–8.0, 8.0–9.0, 9.0–10.0, 10.0–10.5, 10.5–11.0, 11.0–12.0, and 12.0+ g/dL. Health state descriptions were reviewed by clinicians and two quality-of-life experts. Eighty-five members of the general public were asked to rate the health states using a visual analogue scale and standard gamble (SG). Twenty-six oncology patients were interviewed using the time trade-off (TTO).
The mean societal SG derived utility values showed a significant linear change from 0.583 ± 0.067 (7–8 g/dL hemoglobin [Hb]) to 0.708 ± 0.057 (12+ g/dL Hb). The patient TTO data ranged from 0.297 ± 0.127 (7–8 g/dL Hb) to 0.611 ± 0.092 (12+ g/dL Hb).
The health state utility scores from both groups show a decrement in line with worsening anemia. Furthermore, patients who have experienced cancer-related fatigue rate the more severe levels of anemia much lower than the general public.